Figure 6
Response of osteosarcoma (OS) cells and sCLU or shRNA-sCLU transfected OS cells grown as orthotopic xenografts to cisplatin (DDP). (A) KH OS, KHOS/sCLU, KHOS/pCDNA3.1 tumors were treated with DDP for four weeks. #P < 0.05, KHOS/sCLU versus KHOS (or KHOS/pCDNA3.1); ##P < 0.05, KHOS/sCLU/DDP versus KHOS/DDP (or KHOS/pCDNA3.1 DDP); (B) sCLU and pERK1/2 expression were detected by Western blot assay. (C) U-2 OS, U-2 OS/sCLU-shRNA-1, U-2 OS/sCLU-shRNA-2 and U-2 OS/shRNA tumors were treated with DDP for 4 weeks. *P < 0.05, U-2 OS(or U-2 OS/shRNA) versus U-2 OS/sCLU-shRNA-1 and U-2 OS/sCLU-shRNA-2; **P < 0.05, U-2 OS/sCLU-shRNA-1/DDP and U-2 OS/sCLU-shRNA-2/DDP versus U-2 OS/DDP (or U-2 OS/shRNA/DDP); (D) sCLU and pERK1/2 expression were detected by Western blot assay.